Quantcast

FDA approves new treatment for social anxiety disorder

The U.S. Food and Drug Administration has approved Effexor XR for the treatment of patients with social anxiety disorder, a condition which may affect up to 13 percent of Americans at some point in their lives. EFFEXOR XR, already approved for the treatment of depression and generalized anxiety disorder (GAD), is the first available serotonin-norepinephrine reuptake inhibitor (SNRI), and is believed to increase the levels of two key brain chemicals thought to be deficient in individuals suffering from depression and anxiety disorders.